🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⭐️Dr. Pedro Barata gives a very thoughtful discussion of how to navigate 1st line RCC data in 2025 to provide best care for our patients. LOVE the updated table below. #AtlantaGU25 Binaytara Yousef Zakharia Mehmet Asim Bilen,MD Rohan Garje, MD Baptist Health Winship Cancer Institute of Emory University Binaytara

Time for the kidney cancer session #AtlantaGU25 led by Pedro C Barata, MD MSc FACP and Benjamin L Maughan with Viraj Master and Mehmet Asim Bilen,MD great updates in both the clear cell and non clear cell space Binaytara

⭐️ Phenomenal talk by Dr. Benjamin Maughan on the latest 2025 update for non clear cell RCC. Thought provoking discussion of combination vs sequential treatments. Also chromophobe RCC has better than expected results in SUNNIFORECAST #AtlantaGU25 Binaytara Yousef Zakharia

⭐️LOVE this panel discussion format at #AtlantaGU25 . Key opinion thought leaders in RCC provide their thoughts on tough challenging cases brought in by community oncologists. Binaytara Yousef Zakharia Mehmet Asim Bilen,MD Rohan Garje, MD Baptist Health Winship Cancer Institute of Emory University Binaytara

Huge achievement Jordan Ciuro, MD big congratulations

Last session is rare GU cancers, with fantastic lineup Binaytara Yousef Zakharia

Phase 2 single-arm #Clinicaltrial of neoadjuvant cabozantinib in patients with locally advanced nonmetastatic ccRCC, assesses efficacy and finds antitumor CD8+ T cell response activation upon treatment. by Mehmet Asim Bilen,MD Viraj Master Haydn Kissick ⬇️ nature.com/articles/s4301…

View cutting-edge presentations on recent advancements for treating kidney cancer with Society for Immunotherapy of Cancer’s #virtual Advances in Cancer Immunotherapy™: A Focus on Bladder and Genitourinary program April 7. Register now: ow.ly/y6vC50VoSHB #LearnACI Stephanie Berg Mehmet Asim Bilen,MD Shilpa Gupta

Thank you ASCO for the opportunity to discuss: 🔎De-escalating Treatment in De Novo Oligometastatic Prostate Cancer: Which Patients Benefit? 📌dailynews.ascopubs.org/do/de-escalati… Check out our thoughts and current research⬆️ The ASCO Post & Thank you mentors Mehmet Asim Bilen,MD &ShahidAhmed

Amazing discussion and review of ASCO data in updates in metastatic urothelial cancer from friend & colleague Jacqueline T. Brown, MD 👏 Key Points in mUC: ✅Sacituzumab govitecan is an area of interest but concern for AE such as neutropenia. Might not be the right drug for maintenance

🔎ALLO-316 (allogeneic CD70 CAR-T) in ccRCC? Updates from ph1 TRAVERSE ✅ORR 31% after single dose of ALLO316 in met ccRCC ✅Safety was manageable Underscores the potential of CAR-T in solid tumors ASCO @oncoalert @Oncolive Targeted Oncology MEDTRACK @Urotoday #ASCO25

🔎Role of DB-1311/BNT324 (novel B7H3 ADC) in CRPC patients who are heavily pretreated? ✅Agent showed efficacy; among 52 pts: ORR seen in 42.3%, DCR 90.4%, 6m rPFS 67.7% ✅Outcomes appeared better in earlier treatment lines Currently enrolling post Lu-177 CRPC and taxane naive

🔎Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC vs Lu-PSMA: ph2 EVOLUTION; ANZUP2001 ✅PSA PFS at 12m 33 vs 17% ✅Median rPFS 12m vs 8.5m ✅PSA 50 RR 75% vs 67% ✅Grade 3-4 AE 76% vs 29% ✖️Signal of activity, but closed at 93/100 after 4 cases of myocarditis. Further

🔎Phase 1 results of JNJ-78278343 (pasritamig) in mCRPC? A first in class bispecific T-cell engager targeting human kallikrein2... a specific prostate antigen ✅Remarkable safety profile differentiated from prior T-cell engages with/ low rates of TRAE and infrequent CRS (8.9%,

🔎 Ph2 trial of nivolumab + ipilimumab +/- SBRT in mCRPC? Role of SBRT on metastasis and IO in CA209-8TY trial ➡️PSA response rate of 21.6 % vs 20.% ➡️ORR 16.7 % vs 22.2% ✖️SBRT did not increase response or OS Treatment with checkpoint inhibitors in mCRPC should be

🔎Exploratory analyses of HRRm by gene subgroup and associations with efficacy from TALAPRO2? ✅ Cohort 2 of TALAPRO2 shows improved rPFS and OS in mCRPC and HRRd with talazoparib + enza vs enza monotherapy ➡️ Most pronounced in BRCA1/2 and CDK12 Limitations: retrospective

🔎Clonal hematopoiesis (CH) in mCRPC receiving Lu-PSMA617 or cabazitaxel? A post-hoc analysis of TheraP; ANZUP ➡️In mCRPC, CH mutations more frequent with Lu-PSMA617> than cabazitaxel chemotherapy (3.2x) but also commonly found at baseline (76% prior to either therapy) ➡️Most

Finally had a chance to listen to the discussion EVERYONE in the GU community is talking about via ASCO Virtual Meeting. One of the most thoughtful & eloquent discussions I have ever seen by Jacqueline T. Brown, MD Winship Cancer Institute of Emory University, summarizing excellent presentations from Michiel van der Heijden

#JIPO received its 1st official #impactfactor = 3.2! Immunology/Oncology Rank: Q2/Q3 We thank everyone who contributed to this achievement! Aung Naing Innovations Journals Innovative Oncology Network Jibran Ahmed Yostena Mekhail, MD, PhD @mderbalamd Maria Hafez Carlos Torrado Sewanti Limaye 🇮🇳🇺🇸 Gil Morgan, MD